Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A panel of federal health experts recommended expanded vaccine options for several diseases, including RSV, meningitis, and chikungunya.

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

Accessing a life-saving winter bug vaccine has been made easier by the Government this year.Last year people aged between 75 ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy ...

78.5% of unvaccinated adults are unsure if they were eligible for vaccination or thought they were not. HealthDay News — Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine ...

According to a recent study, adults who suffer from respiratory syncytial ... Anyone experiencing these symptoms — especially those with a history of RSV-ARI — should consult a doctor as soon as ...

ADULTS diagnosed with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face nearly triple the risk of death within 1 year compared to their peers, according to a ...